SQA
CRVS icon

Simon Quick Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Simon Quick Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Buy
+25,000
New +$347K 0.02% 300

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Simon Quick Advisors's CRVS Position: Q2 2026 in Review

Simon Quick Advisors opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 25,000 shares worth $374K. The stake represents 0.02% of the portfolio and ranks #300 among its holdings.

173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Simon Quick Advisors held 25,000 shares of Corvus Pharmaceuticals worth $374K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Simon Quick Advisors position in Q2 2026.
  • Corvus Pharmaceuticals made up 0.02% of Simon Quick Advisors's portfolio in Q2 2026, its #300 holding.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Simon Quick Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.